Latest Content

This is the fourth time the antimicrobial bill looking at a subscription-payment model has been introduced in the Congress and has some updates in how these therapeutics are developed and paid for with help from the federal government.

In the latest From Pathogen to Infectious Disease Diagnosis podcast, Andrea Prinzi, PhD, MPH, SM(ASCP), talks about diagnostic stewardship and that when it is grounded in collaboration, education, and thoughtful test use, it can improve patient care while helping clinicians navigate increasingly complex diagnostic tools.

Findings from a growing body of randomized trials and real-world analyses show that starting metformin during acute SARS-CoV-2 infection is safe and significantly reduces the risk of developing long COVID.

Paul Offit, MD, voices concerns over the CDC’s surveillance capabilities, the federal agency’s lack of movement to address vaccine needs during outbreaks, and diminishing herd immunity, making the vulnerable at risk for contracting disease.

A global review finds growing antimicrobial resistance among the main bacteria causing meningitis—especially in low- and middle-income countries—raising concerns about the continued effectiveness of standard treatments and the urgent need for stronger surveillance.

As the spending bill makes its way through Congress, the HIV+Hepatitis Policy Institute's Carl Schmid provides some insights on the latest wranglings on the HIV bill and the domestic programs.

MicuRx Pharmaceuticals has received FDA clearance to begin a phase 2a clinical trial of MRX-5, a novel oral antibacterial therapy for patients with Mycobacterium abscessus pulmonary disease.

In the second installment of our 2-part interview, infectious disease pediatrician Sharon Nachman, MD, discusses this very rare adverse effect that can occur after immunization administration.

This week, read about the latest number of confirmed cases of measles in the US, novel findings around UTI treatment failure, an overview of zoliflodacin and gepotidacin, and more.

The American Academy of Pediatrics (AAP) has published its 2026 immunization schedule, reaffirming routine vaccination to protect children and adolescents against 18 preventable diseases.

Infectious disease pediatrician Sharon Nachman, MD, discusses the vaccine data the federal agency disclosed in the recent letter they sent to the manufacturers.

Fedora Pharmaceuticals is presenting new preclinical data at the IMARI conference demonstrating that its lead candidate, FPI-2119, shows strong activity against some of the most dangerous drug-resistant Gram-negative infections, supporting its advancement toward clinical trials.

This past December, the FDA approved both zoliflodacin and gepotidacin for this sexually transmitted infection marking a significant advance amid rising antibiotic resistance. Here is an overview of the antibiotics.